DrugBiological
Navicixizumab clinical trials
Also written OMP-305B83.
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
OncoMed Pharmaceuticals, Inc. (3) · OncXerna Theraputics, Inc. (2)
Often tested with
Tested in the same studies.
Paclitaxel (2) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1) · Folfox protocol (1) · Irinotecan (1)
Studies
Open first, then newest update. How each study uses navicixizumab is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid TumorsStatus unknownPhase 2OncXerna Theraputics, Inc.NCT05453825Written as navicixizumab+paclitaxel
- A Study of Navicixizumab in Patients With Platinum Resistant Ovarian CancerStatus unknownPhase 3OncXerna Theraputics, Inc.NCT05043402Written as navicixizumab
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerCompletedPhase 1OncoMed Pharmaceuticals, Inc.NCT03030287Written as OMP-305B83
- A Phase 1 Study of OMP-305B83 in Subjects With Solid TumorsCompletedPhase 1OncoMed Pharmaceuticals, Inc.NCT02298387Written as OMP-305B83
- A Study of OMP-305B83 in Subjects With Metastatic Colorectal CancerTerminatedPhase 1OncoMed Pharmaceuticals, Inc.NCT03035253Written as OMP-305B83
Codes
What other systems call navicixizumab · ClinicalTrials.gg INT001266
- MeSH (NLM) C000657345navicixizumabOne source NLM
- UNII (FDA) 1W14T9L25WNAVICIXIZUMABConfirmed FDA, NLM
- NCI Thesaurus C119620NavicixizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000657345 | navicixizumab | One source NLM |
| UNII (FDA) | 1W14T9L25W | NAVICIXIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C119620 | Navicixizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.